United States Patent 8,754,109: Pirfenidone CYP1A2 Inducer Avoidance Claims and Patent Landscape
US Patent 8,754,109 protects a method of administering pirfenidone while avoiding a strong CYP1A2 inducer, particularly cigarette smoke. Its commercially important embodiments cover idiopathic pulmonary fibrosis, pirfenidone doses of 1,800 mg or more per day, a 2,400 mg or 2,403 mg daily dose, 801 mg tablets administered three times daily, and administration with food. The patent is a method-of-use patent. It does not broadly claim pirfenidone, a pirfenidone composition, or every treatment of pulmonary fibrosis.
The patent was granted June 17, 2014, to InterMune, Inc. Its nominal patent term runs to December 14, 2030, subject to any applicable patent-term adjustment or correction reflected in the USPTO record (U.S. Patent No. 8,754,109, 2014).
What does US Patent 8,754,109 cover?
The patent covers increasing pirfenidone exposure by avoiding a strong inducer of CYP1A2 in a patient receiving pirfenidone therapy. The central clinical premise is that CYP1A2 induction increases pirfenidone metabolism and can reduce systemic exposure. Cigarette smoking is the principal expressly claimed example.
Independent claim 1
Claim 1 requires all of the following:
- A patient is in need of pirfenidone therapy.
- The patient is taking a strong CYP1A2 inducer.
- Pirfenidone is administered in a therapeutically effective amount.
- The strong CYP1A2 inducer is avoided.
- The purpose or result is increasing the effectiveness of pirfenidone therapy by avoiding decreased pirfenidone exposure.
The claim is narrower than a general instruction to stop smoking during pirfenidone treatment. It requires the relationship between pirfenidone therapy, the inducer, and avoidance of decreased exposure. A method that does not involve a strong CYP1A2 inducer would not meet the express limitations of claim 1.
Dependent claims
| Claims |
Added limitation |
Commercial relevance |
| 2, 5, 7, 12, 13, 15, 17 |
Idiopathic pulmonary fibrosis or a fibrosis condition |
Targets Esbriet's principal indication and related fibrosis uses |
| 4, 5, 14, 15 |
Total daily dose of at least 1,800 mg |
Covers high-dose therapy, including standard maintenance dosing |
| 6, 7, 16, 17 |
Total daily dose of 2,400 mg or 2,403 mg |
Captures the labeled 801 mg three-times-daily regimen |
| 8 |
Each dose is 801 mg |
Targets the commercial tablet strength |
| 9, 18 |
Administration three times daily |
Matches the standard maintenance schedule |
| 10, 19 |
Administration with food |
Tracks the labeled administration instruction |
| 11-19 |
Strong inducer is cigarette smoke |
Narrows the claims to smoking-related CYP1A2 induction |
Claims 11 through 19 are particularly important because they convert the broader CYP1A2-inducer claims into smoking-specific claims. A generic or authorized generic label that instructs patients to stop smoking while taking pirfenidone could create a potential induced-infringement issue if the patent remains enforceable and the label satisfies the remaining claim limitations.
How should the claims be construed?
What is a “strong inducer” under the patent?
The claims use the phrase “strong inducer of cytochrome P450 1A2.” The specification and regulatory labeling provide the relevant pharmacokinetic context. Cigarette smoke induces CYP1A2 and is treated in the claims as the specific strong inducer.
The claim does not expressly identify every drug or environmental exposure that may induce CYP1A2. A dispute over another inducer would likely turn on the patent specification, the pharmacology evidence, regulatory definitions, and the ordinary meaning of “strong” in the relevant technical field.
Does the claim require smoking cessation?
Claims 1 through 10 are not limited to cigarette smoke. They cover avoiding a strong CYP1A2 inducer generally. Claims 11 through 19 require cigarette smoke specifically.
For infringement purposes, “avoiding” may be satisfied by conduct such as smoking cessation, preventing exposure, or discontinuing an inducing drug, depending on how a court construes the claim and evaluates the accused regimen. The claims do not require a particular smoking-cessation program, duration, biomarker, or measured increase in pirfenidone concentration.
Does the claim require a measured increase in exposure?
The claims are drafted as treatment-method claims. They recite increasing effectiveness by avoiding decreased exposure, but the dependent claims do not expressly require a measured plasma concentration, area-under-the-curve result, or specific clinical endpoint.
A product label or treatment protocol could therefore create risk without requiring the manufacturer to measure each patient's pirfenidone exposure. The principal issue would be whether the prescribed conduct satisfies the method limitations.
What pirfenidone dosing regimens are protected?
The strongest commercial overlap is with the approved Esbriet dosing regimen.
Dose hierarchy
The claims create several nested dosing positions:
- At least 1,800 mg per day: claims 4, 5, 14, and 15.
- Exactly 2,400 mg or 2,403 mg per day: claims 6, 7, 16, and 17.
- 801 mg per dose: claim 8.
- 801 mg three times daily: claims 9 and 18 when read through claim 6 or claim 16.
- 801 mg three times daily with food: claims 10 and 19 when read through the relevant preceding claims.
The 2,403 mg figure corresponds mathematically to three 801 mg doses. The alternative 2,400 mg figure may capture a rounded or formulation-specific description of the same high-dose regimen.
Scope by regimen
| Regimen |
Likely claim position |
| 801 mg once daily |
Potentially claim 8, if all claim 1 limitations are met |
| 801 mg twice daily |
Potentially claim 8, but not claims requiring three-times-daily dosing |
| 801 mg three times daily |
Claims 8 and 9, with claim 6 or 16 providing the daily-dose limitation |
| 801 mg three times daily with food |
Claims 8-10 or 18-19 |
| 1,800 mg or more per day using another strength |
Claims 4 or 14, if the inducer and avoidance limitations are met |
| Pirfenidone below 1,800 mg per day |
May remain within claim 1, but not claims 4-7 or 14-17 |
A lower-dose regimen does not automatically avoid the patent because claim 1 has no express 1,800 mg minimum. Conversely, a high-dose regimen alone does not infringe. The CYP1A2-inducer and avoidance limitations remain essential.
What is the patent's geographic coverage and term?
US 8,754,109 provides protection only in the United States. It does not directly block conduct in Europe, Japan, China, Canada, or other markets. Parallel foreign applications or national-stage patents must be analyzed separately.
| Event |
Date or status |
| Patent |
US 8,754,109 |
| Title |
Methods of increasing the effectiveness of pirfenidone therapy |
| Grant date |
June 17, 2014 |
| Original assignee |
InterMune, Inc. |
| Commercial successor |
Roche/Genentech following Roche's acquisition of InterMune |
| Nominal expiration |
December 14, 2030 |
| Patent type |
Method of treatment/method of use |
| Product relationship |
Pirfenidone, marketed in the US as Esbriet |
The December 14, 2030 date is based on the patent family's filing-term framework. Any patent-term adjustment, terminal disclaimer, correction, or later USPTO record should control the operative expiration date.
What is the Orange Book status of US 8,754,109?
US 8,754,109 is associated with the US patent estate for Esbriet, pirfenidone's FDA-approved product for idiopathic pulmonary fibrosis. The relevant regulatory framework is the Hatch-Waxman system. An Orange Book-listed method-of-use patent can require an ANDA applicant to certify under Paragraph IV that the patent is invalid, unenforceable, or not infringed, or to submit a section viii statement that the applicant is not seeking approval for the patented use (FDA, 2024a; 21 U.S.C. § 355(j)).
The commercial significance depends on the use code attached to the listing. If the use code is limited to avoiding CYP1A2 induction or smoking-related exposure reduction, a generic applicant may attempt to carve out the patented use while retaining approval for nonpatented pirfenidone treatment. If the approved labeling still instructs patients to avoid smoking in a way that tracks the claims, the carve-out analysis becomes more difficult.
Relevant FDA labeling
The Esbriet label identifies smoking as a factor that reduces pirfenidone exposure and instructs patients to stop smoking. The label also establishes the 801 mg tablet and the 801 mg three-times-daily maintenance regimen, generally administered with food. Those directions closely correspond to claims 6 through 10 and 16 through 19 (FDA, 2024b).
Which companies are challenging the patent?
A company-specific Paragraph IV analysis requires current FDA Orange Book data, ANDA certifications, Abbreviated New Drug Application litigation records, and settlement filings. The claim text alone does not identify a challenger.
For business analysis, the relevant risk categories are:
- Paragraph IV challenge. The applicant alleges that US 8,754,109 is invalid, unenforceable, or not infringed.
- Section viii carve-out. The applicant omits the patented use from its labeling.
- Noninfringement through label design. The generic label avoids instructions corresponding to CYP1A2-inducer avoidance.
- Validity challenge. The applicant argues anticipation, obviousness, indefiniteness, written-description, enablement, or lack of patentable subject matter.
- Launch at risk. The applicant launches before final resolution of patent litigation.
The patent presents a greater label-induced-infringement risk when a generic applicant retains instructions specifically directing patients who smoke to stop smoking while taking pirfenidone. A narrow section viii carve-out may reduce that risk, but it may also limit the commercial usefulness of the generic label for the principal FDA-approved population.
How strong is the patent estate for pirfenidone?
US 8,754,109 is strongest as a late-expiring, clinically specific method patent tied to the labeled product regimen. Its principal strengths are:
- Direct overlap with the approved 801 mg tablet and three-times-daily schedule.
- Express coverage of cigarette smoke, a commercially common CYP1A2 inducer.
- Multiple dependent claims creating alternative infringement positions.
- A nominal expiration date materially later than the original composition-of-matter period.
- Potential relevance to generic labeling and induced infringement.
Its principal vulnerabilities are:
- It does not claim pirfenidone itself.
- It requires the patient to be taking, or exposed to, a strong CYP1A2 inducer.
- The claim language may create disputes over the meaning of “strong,” “avoiding,” and “increasing effectiveness.”
- Prior pharmacokinetic evidence concerning smoking, CYP1A2 induction, and pirfenidone exposure could support an obviousness challenge.
- A generic applicant may seek a use carve-out or design a label that does not affirmatively instruct the patented conduct.
The claims are therefore commercially meaningful but behavior-dependent. They are not a complete barrier to all pirfenidone competition.
What other patent barriers affect generic pirfenidone?
Pirfenidone competition may implicate several patent categories:
Composition and pharmaceutical formulation patents
Earlier pirfenidone patents may cover the active ingredient, pharmaceutical compositions, salt or particle characteristics, or dosage forms. Those patents generally have earlier expiration dates than US 8,754,109 if they claim the original compound or basic composition.
Method-of-use patents
Other patents in the Esbriet estate may cover treatment of idiopathic pulmonary fibrosis, dosing regimens, or clinical use. A generic applicant must assess each Orange Book-listed patent separately. Avoiding US 8,754,109 does not necessarily eliminate exposure under another method-of-use patent.
Manufacturing and process patents
Process claims may cover purification, crystallization, particle-size control, tablet manufacture, or commercial-scale production. Such patents can remain relevant even when a generic successfully avoids product and method-of-use patents, although process patents normally create a different enforcement posture from Orange Book-listed patents.
Biosimilar risk
Biosimilar risk is not applicable to pirfenidone. Pirfenidone is a small-molecule drug approved through an NDA, not a biologic approved under the Public Health Service Act. Competition proceeds through the ANDA pathway, not the biosimilar pathway.
What generic launch scenarios are most plausible?
| Scenario |
Effect on US 8,754,109 |
| Generic label excludes smoking-related instructions |
Reduces direct label overlap but may limit use coverage |
| Generic label repeats smoking-cessation instructions |
Increases induced-infringement exposure |
| Paragraph IV litigation |
Could produce an early judgment on validity and scope |
| Settlement with delayed launch |
Preserves potential market exclusivity while avoiding trial risk |
| Launch after patent expiration |
Eliminates ordinary infringement risk from this patent |
| At-risk launch before expiration |
Creates damages, injunction, and treble-damages exposure if infringement is found |
Revenue exposure is concentrated in the standard maintenance population because the patent claims track the commercial 801 mg regimen. The patent is less relevant to pirfenidone use that does not involve a strong CYP1A2 inducer, cigarette smoke, or the claimed high-dose schedules.
Key Takeaways
- US 8,754,109 is a method-of-use patent, not a basic pirfenidone composition patent.
- Claim 1 requires pirfenidone treatment, a strong CYP1A2 inducer, and avoidance of that inducer.
- Claims 11 through 19 specifically target cigarette smoke.
- The most commercially important claims cover 801 mg three times daily, 2,400 mg or 2,403 mg per day, and administration with food.
- The nominal expiration date is December 14, 2030.
- Generic risk is driven primarily by labeling and induced-infringement theories.
- Pirfenidone has generic, not biosimilar, competition.
- The patent does not block all pirfenidone products or all idiopathic pulmonary fibrosis treatments.
- Other Orange Book-listed and non-Orange-Book patents must be analyzed separately before assessing launch freedom.
FAQs
Does US 8,754,109 cover every patient taking Esbriet?
No. The patient must also be taking or exposed to a strong CYP1A2 inducer, and the method must involve avoiding that inducer.
Does smoking one cigarette create patent infringement?
The claims do not establish a quantitative smoking threshold. Infringement would depend on whether the accused treatment satisfies the strong-inducer and avoidance limitations as construed by a court.
Can a generic pirfenidone manufacturer omit the smoking warning?
A generic label must remain consistent with FDA requirements. A manufacturer may seek a section viii carve-out, but the success of that strategy depends on the FDA use code, the proposed label, and whether the remaining label induces the patented method.
Is 1,800 mg per day required for infringement?
No. Claims 4, 5, 14, and 15 require at least 1,800 mg per day, but claim 1 does not contain that minimum-dose limitation.
Does the patent cover pirfenidone treatment outside idiopathic pulmonary fibrosis?
Potentially. Claim 1 is not limited to idiopathic pulmonary fibrosis. Claims 3 and 13 expressly refer to a fibrosis condition, while claims 2, 5, 7, 12, 15, and 17 specifically recite idiopathic pulmonary fibrosis.
References
-
U.S. Patent No. 8,754,109. (2014). Methods of increasing the effectiveness of pirfenidone therapy. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024b). Esbriet (pirfenidone) prescribing information. Genentech USA, Inc.
-
21 U.S.C. § 355(j). Abbreviated applications for new drugs.
-
U.S. Patent and Trademark Office. (2024). Patent Center and patent term adjustment records.
